Cargando…

Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma

Using tissue whole exome sequencing (WES) and circulating tumor cell–free DNA (ctDNA), this Australasian Leukaemia & Lymphoma Group translational study sought to characterize primary and acquired molecular determinants of response and resistance of marginal zone lymphoma (MZL) to zanubrutinib fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tatarczuch, Maciej, Waltham, Mark, Shortt, Jake, Polekhina, Galina, Hawkes, Eliza A., Ho, Shir-Jing, Trotman, Judith, Brasacchio, Daniella, Co, Melannie, Li, Jessica, Ramakrishnan, Vanitha, Dunne, Karin, Opat, Stephen S., Gregory, Gareth P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368859/ https://www.ncbi.nlm.nih.gov/pubmed/36947202 http://dx.doi.org/10.1182/bloodadvances.2022009412

Ejemplares similares

P1261: ALLG LABORATORY SCIENCE STUDY LS21: MOLECULAR CORRELATES OF RESPONSE IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (RRMZL) PATIENTS TREATED WITH ZANUBRUTINIB IN THE MAGNOLIA TRIAL
por: Tatarczuch, M., et al.
Publicado: (2022)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL
por: Yano, Max, et al.
Publicado: (2022)

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
por: Bonfiglio, Silvia, et al.
Publicado: (2023)

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway
por: Butler, Miriam, et al.
Publicado: (2021)

High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL
por: Chiodin, Giorgia, et al.
Publicado: (2022)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)

Retrospective characterization of nodal marginal zone lymphoma
por: Stuver, Robert, et al.
Publicado: (2023)

Unraveling the genetics of transformed splenic marginal zone lymphoma
por: Grau, Marta, et al.
Publicado: (2023)

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network
por: Hapgood, Greg, et al.
Publicado: (2023)

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data
por: Horwitz, Steven M., et al.
Publicado: (2021)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma
por: Silva, Ana, et al.
Publicado: (2021)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression
por: Gupta, Vikas A., et al.
Publicado: (2021)

COVID-19 in patients with CLL: how can we change the odds?
por: Herishanu, Yair, et al.
Publicado: (2021)

The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5
por: Manfroi, Benoît, et al.
Publicado: (2021)

Nras(Q61R/+) and Kras(−/−) cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors
por: Wen, Zhi, et al.
Publicado: (2021)

Toward prevention of childhood ALL by early-life immune training
por: Hauer, Julia, et al.
Publicado: (2021)

Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia
por: Duault, Caroline, et al.
Publicado: (2021)

Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL
por: Akahane, Koshi, et al.
Publicado: (2022)

Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study
por: Lynggaard, Line Stensig, et al.
Publicado: (2022)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
por: Wieduwilt, Matthew J., et al.
Publicado: (2022)

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab
por: Bruscaggin, Alessio, et al.
Publicado: (2021)

A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
por: Isaksen, Kathrine T., et al.
Publicado: (2021)

CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication
por: Mayerhoefer, Marius E., et al.
Publicado: (2022)

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study
por: Haydu, J. Erika, et al.
Publicado: (2022)

ORP4L is a prerequisite for the induction of T-cell leukemogenesis associated with human T-cell leukemia virus 1
por: Zhong, Wenbin, et al.
Publicado: (2022)

The molecular hallmarks of primary and secondary vitreoretinal lymphoma
por: Bonzheim, Irina, et al.
Publicado: (2022)

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas
por: Koh, Min Jung, et al.
Publicado: (2022)

Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
por: Charalampous, Charalampos, et al.
Publicado: (2022)

Distinct clinical and genetic features of hepatitis B virus–associated follicular lymphoma in Chinese patients
por: Ren, Weicheng, et al.
Publicado: (2022)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
por: Harkins, R. Andrew, et al.
Publicado: (2022)

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma
por: Maziarz, Richard T., et al.
Publicado: (2022)

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia
por: Jiang, Chuang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a6jlcn8vsk2lmpma1ij9of72l0